Free tool
Drug Trial Radar
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 19, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
7,024
Recruiting, industry sponsors
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting7,024
- Not yet recruiting2,256
- Completed64,782
7,024 trials
Showing 1 to 25, recently updated first.
- A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's DiseaseRecruiting
SanofiSanofi (SNY)
NCT06958536 · 99 participants (planned) · Start Jun 3, 2025 · Primary completion Dec 17, 2026
Drug: brivekimig; Placebo · For: Crohn's Disease
Sites: Fairhope, Alabama; Tucson, Arizona; Escondido, California · 78 sites in all
Singulera Therapeutics Inc.Industry
NCT06552169 · 34 participants (planned) · Start Jun 13, 2025 · Primary completion Dec 2027
Drug: Arm 1: SOC (mTOR + CNI); Arm 2A: TRACT/MONO mTOR and 1 more · For: Kidney Transplantation
Sites: Phoenix, Arizona; Chicago, Illinois; Rochester, Minnesota · 7 sites in all
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07850752 · 340 participants (planned) · Start Nov 11, 2026 · Primary completion Sep 17, 2028
Drug: zigakibart; atrasentan and 1 more · For: IgA Nephropathy (IgAN)
Sites: Huntsville, Alabama; Fremont, California; Newark, Delaware · 11 sites in all
AbbVieAbbVie (ABBV)
NCT07525206 · 990 participants (planned) · Start May 22, 2026 · Primary completion May 2029
Drug: Telisotuzumab adizutecan; Bevacizumab and 1 more · For: Colorectal Cancer
Sites: Goodyear, Arizona; Springdale, Arkansas; Duarte, California · 91 sites in all
AbbVieAbbVie (ABBV)
NCT07673107 · 94 participants (planned) · Start Jun 23, 2026 · Primary completion Nov 2028
Drug: AGN-151607-DP; Placebo for AGN-151607-DP · For: Upper Limb Essential Tremor
Sites: Carlsbad, California; Fresno, California; Fullerton, California · 22 sites in all
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringePivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07890909 · 40 participants (planned) · Start Nov 13, 2026 · Primary completion Dec 12, 2027
Drug: Povetacicept; Sibeprenlimab · For: Immunoglobulin A Nephropathy
Sites: Orlando, Florida; Lawrenceville, Georgia
- A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)Pivotal-lookingRecruiting
Relay Therapeutics, Inc.Industry
NCT06789913 · 277 participants (planned) · Start Jun 13, 2025 · Primary completion Jul 2031
Drug: RLY-2608; Placebo · For: PIK3CA-Related Overgrowth Spectrum (PROS); Lymphatic Malformations; Vascular Malformations and 5 more
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 49 sites in all
- Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Pivotal-lookingRecruiting
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT04613596 · 626 participants (planned) · Start Dec 2, 2020 · Primary completion Oct 31, 2028
Drug: Adagrasib; Adagrasib and 3 more · For: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
Sites: Goodyear, Arizona; Prescott Valley, Arizona; Safford, Arizona · 776 sites in all
Stemline Therapeutics, Inc.Industry
NCT05386108 · 73 participants (planned) · Start Aug 31, 2022 · Primary completion Aug 2027
Drug: Elacestrant; Abemaciclib · For: Breast Neoplasms; Brain Neoplasms; Neoplasms by Site and 5 more
Sites: Fullerton, California; Los Angeles, California; Urbana, Illinois · 86 sites in all
- FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCPivotal-lookingRecruiting
Bicara TherapeuticsIndustry
NCT06788990 · 650 participants (planned) · Start Jan 28, 2025 · Primary completion Apr 2028
Drug: Ficerafusp alfa; Pembrolizumab (KEYTRUDA®) and 1 more · For: Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 242 sites in all
- A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 WeeksPivotal-lookingRecruiting
Phathom Pharmaceuticals, Inc.Industry
NCT07752407 · 500 participants (planned) · Start Sep 25, 2026 · Primary completion Oct 20, 2027
Drug: Vonoprazan; Placebo · For: Symptomatic Non-erosive Gastroesophageal Reflux Disease
Sites: Phoenix, Arizona; Chula Vista, California; Lomita, California · 26 sites in all
- A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07488676 · 150 participants (planned) · Start May 4, 2026 · Primary completion Jul 31, 2029
Drug: ASP546C · For: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma; Pancreatic Adenocarcinoma
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 35 sites in all
Wuhan KadGeno Biotechnology Co., LtdIndustry
NCT07948083 · 304 participants (planned) · Start Jan 6, 2026 · Primary completion Nov 30, 2027
Drug: KDTV001 · For: HPV (Human Papillomavirus)-Associated; HPV 16/18; HPV 52 and 1 more
Sites: Wuhan, China · 2 sites in all
AeroRx Therapeutics Inc.Industry
NCT07896252 · 64 participants (planned) · Start Nov 1, 2026 · Primary completion Jun 2027
Drug: AERO-001; AERO-002 and 1 more · For: COPD; Chronic Obstructive Pulmonary Disease (COPD); Lung Disease Chronic and 1 more
Sites: London, United Kingdom; Manchester, United Kingdom
- REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07213778 · 2,000 participants (planned) · Start Nov 24, 2025 · Primary completion May 17, 2027
Drug: REGN7508; Acetylsalicylic Acid (ASA) and 1 more · For: Symptomatic Venous Thromboembolism (VTE)
Sites: La Mesa, California; Rancho Mirage, California; Riverside, California · 57 sites in all
Atrium TherapeuticsIndustry
NCT07738107 · 37 participants (planned) · Start Sep 14, 2026 · Primary completion May 2028
Drug: ATR 1072 · For: Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic and 1 more
Sites: Kansas City, Missouri; Houston, Texas
TRIANA Biomedicines, Inc.Industry
NCT07491497 · 160 participants (planned) · Start Mar 11, 2026 · Primary completion May 31, 2029
Drug: TRI-611 · For: ALK-positive NSCLC; ALK-Positive Lung Cancer; ALK-positive Non-small Cell Lung Cancer
Sites: San Francisco, California; Aurora, Colorado; Boston, Massachusetts · 20 sites in all
- Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Pivotal-lookingRecruiting
Norroy Bioscience Co., LTDIndustry
NCT07795268 · 600 participants (planned) · Start Nov 13, 2026 · Primary completion Nov 30, 2028
Drug: 177Lu-NYM032 injection · For: Prostate Cancer
Sites: Beijing, China
Agomab Spain S.L.U.Industry
NCT07672574 · 8 participants (planned) · Start Sep 9, 2026 · Primary completion Jan 31, 2027
Drug: Ontunisertib; [14C]ontunisertib and 1 more · For: Fibrostenotic Crohn's Disease
Sites: Nottingham, United Kingdom
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07682961 · 850 participants (planned) · Start Jul 14, 2026 · Primary completion Mar 2029
Drug: Lenacapavir; Lenacapavir Tablet and 4 more · For: HIV Infections
Sites: Bakersfield, California; Beverly Hills, California; Hidden Valley Lake, California · 61 sites in all
- A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.Recruiting
Outpace Bio, Inc.Industry
NCT07664735 · 30 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 2030
Drug: OPB-201 · For: Endometrial Cancer Recurrent; Endometrial Cancer; Advanced Endometrial Cancer and 4 more
Sites: San Francisco, California; Atlanta, Georgia; Detroit, Michigan · 5 sites in all
Norroy Bioscience Co., LTDIndustry
NCT07768306 · 20 participants (planned) · Start Nov 8, 2026 · Primary completion Mar 2027
Drug: 68Ga-NYM096 injection · For: Clear Cell Renal Cell Carcinoma (ccRCC)
Sites: Beijing, China
Astellas Institute for Regenerative MedicineAstellas (ALPMY)
NCT03178149 · 42 participants (planned) · Start Jan 30, 2019 · Primary completion Dec 31, 2027
Drug: ASP7317; tacrolimus and 3 more · For: Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Los Angeles, California; Palo Alto, California · 20 sites in all
- A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)Recruiting
ScinnoHub Pharmaceutical Co., Ltd.Industry
NCT07579949 · 30 participants (planned) · Start Jun 16, 2026 · Primary completion Sep 30, 2027
Drug: SNH-119014 dose 1; SNH-119014 dose 2 and 1 more · For: Thalassemia
Sites: Foshan, China; Guangzhou, China; Maoming, China · 8 sites in all
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07140393 · 120 participants (planned) · Start Oct 28, 2025 · Primary completion Oct 2027
Drug: HRS-4508+ Capecitabine; HRS-4508+ Trastuzumab and 8 more · For: Solid Tumor
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.